
News
Filter Results
Displaying 1–10 of 534
-
Oct 2, 2025
Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial
The emerging therapy improved vision for some participants in an earlier clinical trial.
-
Oct 1, 2025
Foundation Fighting Blindness Celebrates Blindness Awareness Month with #ShareYourVision Campaign
This social media campaign amplifies authentic stories from the blind and low vision community to highlight the spectrum of vision loss experiences.
-
Sep 30, 2025
Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.
-
Sep 25, 2025
Foundation Fighting Blindness Announces Over $9 Million in New Research Awards for FY2025
The Foundation Fighting Blindness is proud to announce the funding of 16 innovative research projects in Fiscal Year 2025, totaling over $9 million in new grants.
-
Sep 22, 2025
Agnes Gund – Renowned Philanthropist, Social Justice Champion, and Art Patron – Passes Away
The documentary “Aggie: An Incredible Story of Art and Justice” chronicles her story.
-
Sep 17, 2025
Letter to House Energy & Commerce Committee regarding H.R.1262, the Give Kids a Chance Act.
On behalf of the Foundation Fighting Blindness and the millions of Americans impacted by inherited retinal diseases (IRDs), we urge you to advance H.R.1262, the Give Kids a Chance Act, and reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program.
-
Sep 17, 2025
Give Kids a Chance: Reauthorizing a Lifeline for Children’s Vision
The House Energy & Commerce Committee is considering H.R.1262, the Give Kids a Chance Act, which would reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program.
-
Sep 12, 2025
Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial
NACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.
-
Sep 11, 2025
Recording Available: Insights Forum | Wednesday, August 27, 2025
The Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the blinding diseases community. The call took place on August 27, 2025.
-
Aug 22, 2025
Opus Genetics Receives FDA Clearance to Launch Clinical Trial for Best1 Gene Therapy
The Foundation funded earlier, proof-of-concept studies for the Best1 gene therapy and later launched Opus to develop several IRD gene therapies.